Zhitong Finance App News, BeiGene (688235.SH) announced that the company's product Baiyueda® (BEQALZI™) has obtained accelerated approval from the US Food and Drug Administration (FDA) to treat adult patients with recurrent or refractory (R/R) mantle cell lymphoma (MCL) who have previously received at least two line system treatments (including Bruton's tyrosine kinase (BTK) inhibitors).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.